Cyclosporine, Whole Blood, Immunoassay
Also known as: Cyclosporine A, Whole Blood, Gengraf®, Neoral®, Restasis®, Sandimmune®
Use
Cyclosporine is an immunosuppressive agent derived from Tolypocladium inflatum gams, a fungus originally isolated from a Norwegian soil sample. The agent is used extensively to control rejection of organ transplants, especially of liver, heart, or kidney. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocomponent lymphocytes in the G0 and G1 phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T-helper cell is the main target, although the T-suppressor cell may also be suppressed. Cyclosporine also inhibits lymphokine production and release including interleukin-2. Monitoring of blood levels is imperative because the pharmacokinetics of cyclosporine are not only complex, but vary over time in the same patient; thus, blood levels cannot be well predicted from dosing schedules. Furthermore, this drug has a narrow therapeutic window, and significant toxicity at levels above that range. Renal toxicity with eventual renal failure is the most severe complication. Other assays used to assess renal function (ie, BUN, creatinine clearance) should be ordered along with cyclosporine level, since toxicity may begin even with "acceptable" blood levels. Other toxicity includes hypertension, convulsions, tremors, pulmonary edema, and an increased risk of lymphoma. Drugs that enhance the potential toxicity of cyclosporine, include aminoglycoside antibiotics, amphotericin B, acyclovir, ketoconazole, lovastatin, NSAIDS, and ranitidine.
Special Instructions
Given the complex and variable pharmacokinetics of cyclosporine, it is advised that each patient's specimens be analyzed at a single laboratory to minimize assay-dependent variables. Assay results vary with different methods and antibodies, thus consistency in testing location is key.
Limitations
The test requires monitoring of cyclosporine blood levels due to the drug's narrow therapeutic window and complex pharmacokinetics. Toxicity can occur even with 'acceptable' blood levels, affecting renal function and causing complications like hypertension and convulsions. Co-administration with other drugs should be monitored for potential interaction effects on cyclosporine levels.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 14978-1
- 14978-1
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
2 mL
Minimum Volume
0.6 mL
Container
Lavender-top (EDTA) tube
Storage Instructions
Refrigerate.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 1 month |
